2 November 2021
A global study examining the impact of chloroquine / hydroxychloroquine in preventing COVID-19, COPCOV has recruited 3,386 participants as of 26 Oct from sites in Benin, Côte d’Ivoire, Indonesia, Kenya, Mali, Nepal, Pakistan, Zambia, and closed sites in Thailand, Niger and the UK. Last week, the COPCOV team agreed with active site research teams that it will continue to recruit new participants until 30 Nov 2021, with preliminary study results expected Q1 2022.
"After a slow start COPCOV has become the world’s largest study of COVID-19 chemoprophylaxis. Recent recruitment has been extraordinary. It is a great tribute to the participants and all those who have worked so hard on this important study. Let’s hope it provides a definitive answer early next year!" said COPCOV Co-PI, Prof Sir Nick White.
- With thanks to Nick White, Will Schilling and John Bleho for text.
